Medelis.com Site Map
Our Experience in Oncology Clinical Trial Management
- Daniel D. Von Hoff, M.D., F.A.C.P.
- Michael S. Gordon, M.D.
- James T. Gourzis, M.D., Ph.D.
- Sujuan Ba, Ph.D.
- Alan Sandler, M.D.
- James Cassidy MBChB, MD, MSc, FRCP
- Robert T. Bosserman, J.D.
- E. Laughlin (Larry) Flanagan
- David Browning
- Dr. Deirdre Tessman
- Dr. Joseph Sinkule
- Dr. Mike McGarry
- Dr. Inder Makin
- Michael A. Lechter
- "Adaptive Trials" interview with Cytel CEO now available for download
- Oncology thought-leaders Dr. Alan Sandler and Dr. James Cassidy join Medelis’ Medical Advisory Board
- Medelis Expands CRO Services to Devices, Appoints Dr. Inder Makin as VP
- Dan Von Hoff, M.D. Advocates for “Context of Vulnerability,” A Powerful New Paradigm for Targeted Drug Development
- Renowned cancer researcher Dan Von Hoff, M.D. advocates for “The Lost Opportunity in Phase I Oncology Trials"
- Medelis Expands Worldwide CRO Services with New European Division Helmed by Deirdre Tessman, Ph.D.
- Medelis Hires VP Preclinical Studies, Adds Oncology Preclinical Research Services to CRO Portfolio
- Medelis Launches "Peer Perspectives in Oncology" Series
- Medelis Publishes "The Complete Phase Ib: A Proven Approach to Getting to Phase II Faster"
- Medelis Publishes "Preclinical Trials: A Nuanced Approach to Get Into the Clinic Faster"
Contract Research Organizations in Drug Development & Clinical Trials
- Patient Safety in Clinical Trials p1
- Patient Safety in Clinical Trials p2
- Patient Safety in Clinical Trials p3
- Patient Safety in Clinical Trials p4
- Patient Safety in Clinical Trials p5
- The Complete Phase 1B p1
- The Complete Phase 1B p2
- The Complete Phase 1B p3
- Preclinical Studies p1
- Preclinical Studies p2
- Preclinical Studies p3
- The Lost Opportunity in Oncology Phase I Trials p1
- The Lost Opportunity in Oncology Phase I Trials p2
- Context of Vulnerability p1
- Context of Vulnerability p2
- Context of Vulnerability p3
RSS Feeds
